You are hereFebruary 25, 2020
MSC-EV Administration in GvHD Prevention
Researchers led by Mauro Krampera (University of Verona, Italy) recently focused on the immunological characterization of extracellular vesicles (EVs) derived from human bone marrow mesenchymal stem cells (MSCs) regarding their capability to induce regulatory T‐cells (T‐regs) in vitro and in a xenograft mouse model of graft-versus-host-disease (GvHD). Excitingly, this new STEM CELLS study from Dal Collo et al. reported high levels of EV-mediated in vitro immunomodulatory function, from which the team established the EV therapeutic dose for in vivo studies. Encouragingly, the authors observed a significant improvement in both mouse survival and control of acute GvHD onset and progression, thereby confirming EVs as an alternative to whole MSCs for acute GvHD prevention.